TransMedics Group, Inc. (NASDAQ:TMDX) Receives Consensus Rating of “Moderate Buy” from Brokerages

TransMedics Group, Inc. (NASDAQ:TMDX) has been assigned an average rating of “Moderate Buy” from the eight brokerages that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $166.88.

Several analysts have weighed in on the company. Cantor Fitzgerald started coverage on TransMedics Group in a research report on Thursday, June 6th. They issued an “overweight” rating and a $161.00 price objective for the company. Morgan Stanley upped their target price on TransMedics Group from $104.00 to $145.00 and gave the company an “equal weight” rating in a report on Monday, July 15th. JPMorgan Chase & Co. upped their target price on TransMedics Group from $105.00 to $127.00 and gave the company an “overweight” rating in a report on Wednesday, May 1st. TD Cowen upped their target price on TransMedics Group from $130.00 to $175.00 and gave the company a “buy” rating in a report on Friday, June 7th. Finally, Oppenheimer upped their target price on TransMedics Group from $125.00 to $200.00 and gave the company an “outperform” rating in a report on Thursday.

Insider Buying and Selling

In related news, Director David Weill sold 2,500 shares of the company’s stock in a transaction on Friday, May 10th. The stock was sold at an average price of $129.82, for a total value of $324,550.00. Following the sale, the director now directly owns 11,193 shares of the company’s stock, valued at $1,453,075.26. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, Director David Weill sold 2,500 shares of the stock in a transaction on Friday, May 10th. The stock was sold at an average price of $129.82, for a total value of $324,550.00. Following the sale, the director now directly owns 11,193 shares of the company’s stock, valued at $1,453,075.26. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Waleed H. Hassanein sold 30,000 shares of the company’s stock in a transaction on Monday, May 6th. The shares were sold at an average price of $130.07, for a total value of $3,902,100.00. Following the transaction, the chief executive officer now directly owns 61,643 shares in the company, valued at $8,017,905.01. The disclosure for this sale can be found here. Insiders have sold a total of 101,342 shares of company stock valued at $13,642,015 over the last ninety days. Company insiders own 7.00% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of TMDX. Pitcairn Co. raised its stake in shares of TransMedics Group by 1.5% in the first quarter. Pitcairn Co. now owns 5,378 shares of the company’s stock worth $398,000 after buying an additional 78 shares during the period. Signaturefd LLC grew its holdings in TransMedics Group by 26.6% during the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock valued at $67,000 after buying an additional 93 shares in the last quarter. First Horizon Advisors Inc. boosted its holdings in shares of TransMedics Group by 26.8% in the 4th quarter. First Horizon Advisors Inc. now owns 1,049 shares of the company’s stock worth $83,000 after purchasing an additional 222 shares during the period. International Assets Investment Management LLC purchased a new position in shares of TransMedics Group in the 2nd quarter worth approximately $47,000. Finally, Park Avenue Securities LLC boosted its holdings in shares of TransMedics Group by 3.4% in the 1st quarter. Park Avenue Securities LLC now owns 11,374 shares of the company’s stock worth $841,000 after purchasing an additional 372 shares during the period. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Stock Performance

NASDAQ:TMDX opened at $150.10 on Friday. The company has a debt-to-equity ratio of 3.18, a current ratio of 9.72 and a quick ratio of 8.76. TransMedics Group has a 1-year low of $36.42 and a 1-year high of $171.98. The business has a 50 day moving average of $144.02 and a 200 day moving average of $111.05. The company has a market capitalization of $4.94 billion, a price-to-earnings ratio of -441.47 and a beta of 1.99.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $0.35 earnings per share for the quarter, beating the consensus estimate of $0.21 by $0.14. TransMedics Group had a return on equity of 17.37% and a net margin of 0.84%. The firm had revenue of $114.30 million during the quarter, compared to the consensus estimate of $98.84 million. During the same quarter in the previous year, the company posted ($0.03) earnings per share. The business’s revenue was up 117.7% on a year-over-year basis. On average, sell-side analysts predict that TransMedics Group will post 0.81 earnings per share for the current fiscal year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.